Alterity Therapeutics shared its Q1 FY27 cash flow report, showing cash reserves and plans for a Phase 3 trial.

Oct 30, 2026, 6:21 PM ETResultsRead the original at globenewswire.com

Neutral

Alterity reported A$41.3 million in cash and A$1.34 million in operating cash outflow. It raised about A$5.5 million through option exercises and new shares, but its Phase 3 trial is still being prepared, leaving no clear change in outlook.

ATHE · Alterity Therapeutics

AI read · Neutral

The AI's read

The cash and added funds support preparation for the trial, but some of that money came from issuing shares. The trial is still being prepared, and the report gives no trial result or estimate of how long the cash will last. Together, these facts do not show a clear change in Alterity's outlook.

Get alerts for ATHE

Follow Alterity Therapeutics (ATHE) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ATHE

Free on the App Store and Google Play, or on the web.